Liposomal Clodronate for the Treatment of Malignant Histiocytosis
Purpose
The goal of this study is to determine whether liposomal clodronate exhibits anti-tumor activity against malignant histiocytosis (histiocytic sarcoma)
Background
Malignant Histiocytosis (MH, also known as histiocytic sarcoma) is an aggressive tumor derived from macrophages or dendritic cells that develops in multiple sites simultaneously. In most cases the prognosis is poor due to the wide spread of the disease and failure to respond to chemotherapy. Clodronate is a bisphosphonate compound capable of killing macrophage-like cells. Normally, clodronate binds to bone following intravenous administration. To target clodronate to the macrophages/dendritic cells, it has been encapsulated in liposomes composed of tiny, spherical particles of lipids that are taken up by macrophages/dendritic cells. Previous work has shown that liposome clodronate can be taken up by normal macrophages, killing them within a short period of time. In a pilot study, in 2/3 dogs with MH responded to treatment with liposomal clodronate, suggesting that this type of therapy may have activity in MH.
Eligibility Criteria
To be eligible for this trial, dogs must:
- Have a diagnosis of malignant histiocytosis (MH, histiocytic sarcoma)
- Have a life expectancy of at least 6 weeks
- Have not received chemotherapy within 3 weeks of starting the study.
- Have not received radiation therapy for at least 6 weeks prior to study entry.
- Discontinue any NSAIDS or corticosteroids at lease 72 hours prior to starting the study.
Client Compensation
The study covers the cost of the liposomal clodronate. The owner is responsible for all other costs including office visits and bloodwork.
Contact Information
Dr. Cheryl London
clinicaltrials [at] cvm [dot] osu [dot] edu
